Articles

Bridging the Gap: Advancing Cancer Care for All
Since 2022, when World Cancer’s Day “Close the Care Gap” campaign was launched, we have probably all heard this motto. Disparities in cancer care, unfortunately,…
Advancements in Breast Cancer Treatment: Highlights from the ESTRO 2023 Conference
The annual meeting of the European Society for Radiotherapy and Oncology (ESTRO) took place in Vienna from 12 to 15 May, gathering over 6000 professionals.…
Radiotherapy for Esophageal Cancer – The Challenge of a Difficult Site
More than half a million people are diagnosed each year with esophageal cancer. It is the 8th most common cancer type and places sixth regarding…
Perspectives on the implementation of AI-based solutions for Radiation Oncology – Where are we?
One of the main characteristics of humans, compared to most other living creatures, is the ability of making tools. Progress has been linked to discoveries…
MVision AI: your data is protected!
MVision AI not only provides unique AI-powered solutions for Radiotherapy treatment planning but also follows the highest standards of data protection for clinics and their…
Deep learning to generate synthetic CT Images from MR for Radiotherapy treatment planning
The generation of synthetic images has greatly advanced in recent years due to the progress of artificial intelligence. Some of the applications have recently been…
NCCC Evaluation of MVision AI contouring software
S Warren, N Richmond MVision AI software has been under evaluation at NCCC (Newcastle upon Tyne Hospitals NHS Foundation Trust) since 28 February 2022* in…
MVision: 2022 year in review
2022 came to an end. Seeing our names of customers, the number of scans and countries marked on the map, we know, we reached our…
Cancer in Ireland – Raising Survival Rates
Every year, almost 45.000 people in Ireland are diagnosed with cancer, making Ireland the country with the highest cancer incidence in Europe. The 5 most…
Improving Tools to Fight Glioblastoma
 Background Glioblastoma multiforme represents approximately half of the cases of central nervous system malignant tumors. The median age at diagnosis is 64 years, and the…